Eugene Zaika, general director Ukraine and CIS of Pharma Start, a company acquired in October 2015 by Swiss-headquartered Acino Group and one of the leading players in Ukraine, provides insights into the group’s countercyclical investments in Ukraine, while Pharma Start’s ongoing successes prove that the risk taken is actually paying off. He also documents the cultural and operational transformation that he has been bolstering since taking over the helm of the company, as well as his ambitions to establish Pharma Start as a top 5 company in Ukraine within the upcoming years.
When we met with you in 2011, you were director of Nycomed Takeda in Ukraine. Could you briefly explain how Acino acquired a local company in Ukraine, and how you became its general director?
"Beside the stepping up of our manufacturing efficiency, our improvement efforts have also related to the strengthening of our marketing and sales capacity, which I want to bring to the best international practices when it comes to sales force motivation and incentives."
